Global Polycystic Ovary Syndrome (PCOS) Market Trends and Insights
Rising PCOS Prevalence and Diagnosis-Seeking
PCOS affects 8% to 13% of women of reproductive age, while many patients remain undiagnosed or lack an integrated care plan. The 2023 international guideline recognizes serum AMH as an alternative to ultrasound for assessing polycystic ovarian morphology in adults, improving diagnostic access where imaging capacity is limited. This shift shortens the pathway from symptom presentation to laboratory testing and specialist referral. In China, the age-standardized PCOS prevalence ratio increased at an average annual rate of 2.01% from 1990 to 2021, with a further 27% increase projected by 2036. Expanding diagnosis also increases demand for long-term metabolic and reproductive monitoring.Expansion of Fertility Services and Ovulation-Induction Treatment
PCOS is a leading cause of anovulatory infertility, linking the polycystic ovary syndrome market to fertility consultations, ovulation induction, and assisted reproductive services. International clinical guidance recommends letrozole over clomiphene as the first-line ovulation-induction treatment for many patients. Gonadotropin protocols and IVF or ICSI cycles increase care value when oral treatments are insufficient. A 2025 randomized study reported a 35% natural pregnancy rate with weekly semaglutide 1 mg and metformin 1,000 mg twice daily, compared with 15% with metformin alone. Italian guidance also highlights AMH's role in assessing ovarian hyperstimulation risk before stimulation cycles.Lack of PCOS-Specific Regulatory Approvals
The lack of broadly approved PCOS-specific therapies remains a structural constraint on the polycystic ovary syndrome market. Existing medicines primarily address individual symptoms, including ovulatory dysfunction, insulin resistance, menstrual irregularities, and androgen-related symptoms. This fragmented treatment landscape complicates indication-specific pricing and reimbursement while limiting clear regulatory pathways for therapies targeting the underlying disease process. Organon discontinued development of OG-7191, an HSD17β5 inhibitor for PCOS, on December 15, 2025, highlighting the limited late-stage pipeline and the need for regulatory clarity.Other drivers and restraints analyzed in the detailed report include:
- Adoption of AMH Testing as an Alternative to Ultrasound in Adults
- Integrated Management of PCOS-Related Obesity and Insulin Resistance
- Diagnostic and Treatment Costs Outside Public Reimbursement
Segment Analysis
Treatment Type accounted for 77.56% of PCOS product revenue in 2026, supported by the established use of oral contraceptives, insulin sensitizers, and symptom-directed therapies. Pharmaceutical treatment remained the largest subcategory, addressing menstrual, metabolic, androgen-related, and fertility needs. A semaglutide-metformin study reported a 35% natural pregnancy rate for combination therapy, compared with 15% for metformin alone, alongside mean weight loss of 6.09 kg and 2.25 kg, respectively. Surgical options, such as laparoscopic ovarian drilling for clomiphene-resistant patients, remained limited, while assisted reproductive treatment expanded through IVF and ICSI cycles when induction therapies did not achieve pregnancy.Diagnostic Type is projected to grow at a 9.28% CAGR during 2027-2032, making it the fastest-growing product category in the polycystic ovary syndrome market. Hormonal testing includes AMH, luteinizing hormone, follicle-stimulating hormone, and androgen panels, while metabolic testing identifies insulin resistance, dyslipidemia, and glucose dysregulation. A 2026 study reported that LC-MS/MS-based serum free testosterone achieved an AUC of 0.886 for PCOS diagnosis, compared with 0.856 for total testosterone and 0.864 for the free androgen index. Imaging remains relevant for complex cases, while AMH testing and artificial intelligence-based models increasingly support morphology assessment; a 2025 review reported 95%-99% accuracy for detecting polycystic ovarian morphology.
Menstrual-Cycle Regulation held 44.93% of the polycystic ovary syndrome market size in 2026. Combined oral contraceptives and progestin-only regimens remained widely used among patients not seeking immediate pregnancy, reflecting the continued focus on irregular-cycle management. Antiandrogenic contraceptives and spironolactone also supported the management of hyperandrogenism, hirsutism, and acne. The category continued to address a broad patient base, as visible symptoms often prompted initial consultations, even as metabolic care gained prominence.
Fertility and Ovulation Management is forecast to grow at a 10.12% CAGR through 2032, driven by the link between metabolic treatment and conception planning. Current international guidance identifies letrozole as the preferred ovulation-induction agent over clomiphene for many PCOS presentations. AMH testing supports individualized gonadotropin dosing and ovarian hyperstimulation risk assessment before IVF treatment. A 2025 study reported restored ovulatory cycles in 52.5% of previously anovulatory patients treated with semaglutide, supporting referrals from endocrine care to fertility services. Weight and insulin-resistance management is also gaining relevance due to the condition’s cardiovascular risk profile.
Complete Report Scope:
- By Product Type
- Diagnostic Type
- Harmonal Testing
- Metabolic and Blood Testing
- Imaging and Ultrasound
- Others
- Treatment Type
- Pharmacutical Treatment
- Surgical Treatment
- Assisted Reproductive Treatment
- Lifestyle and Nutritional Management Market
- Others
- Diagnostic Type
- By Patient Need
- Fertility and Ovulation Management
- Menstrual-Cycle Regulation
- Hyperandrogenism, Hirsutism, and Acne Management
- Weight and Insulin-Resistance Management
- Others
- By End User
- Hospitals and Clinics
- Endocrinology Clinics
- Gynecology Clinics
- Diagnostic Laboratories
- Primary-Care Clinics
- Academic and Research Institutions
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies and Telehealth Platforms
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 39.88% of the polycystic ovary syndrome market size in 2026, supported by mature fertility infrastructure and broad access to diagnostic services. GLP-1 receptor agonist use among diagnosed patients remains high, with new use among U.S. women with PCOS rising from 0.07% in 2011 to 17.1% in 2025. Tirzepatide accounted for 37.5% of GLP-1 prescriptions in 2024, up from 17.7% in 2023. However, the lack of U.S. Food and Drug Administration approval for PCOS, prior authorization requirements, and out-of-pocket costs may restrict access. Telehealth expands rural specialist access, while provincial ART funding differences in Canada and expanding private insurance pathways in Mexico shape regional demand.Asia-Pacific is projected to expand at a 9.88% CAGR during 2027-2032, the fastest growth rate among geographic segments in the polycystic ovary syndrome market. China accounted for 28.69% of Asian PCOS cases and 14.56% of global cases in 2021, with prevalence projected to increase by 27% by 2036. India remains a major unmet-need market, with prevalence ranging from 3.7% to 22.5% among women of reproductive age, depending on diagnostic criteria. Japan and South Korea are strengthening diagnostic pathways through AMH testing and AI-supported ultrasound interpretation. Insurance disparities and limited access outside major cities continue to influence treatment conversion across the region.
Europe benefits from universal health coverage, specialist networks, and guideline-aligned diagnostic systems. In the United Kingdom, the 2025 National Health Service model estimated annual savings of GBP 284,029 from replacing ultrasound with the assessed AMH pathway. Germany, France, and Italy support diagnosis, monitoring, and treatment through established fertility and endocrinology networks, while the SPIOMET4HEALTH program advances research into dedicated PCOS pharmacotherapy. The Middle East and Africa remain earlier-stage markets, with diagnostic activity concentrated in Gulf Cooperation Council countries and major cities. Brazil drives South American demand through fertility clinic capacity and expanding insurance coverage, while Argentina faces procurement challenges due to macroeconomic conditions.
List of Companies Covered in this Report:
- Abbott Laboratories
- Abbvie
- AstraZeneca
- Bayer
- bioMérieux
- Bio-Rad Laboratories
- Bristol-Myers Squibb
- Danaher
- Roche
- Hologic
- Merck
- Novo Nordisk
- Organon
- Pfizer
- QuidelOrtho
- Sanofi
- Siemens Healthineers
- Takeda Pharmaceuticals
- Teva Pharmaceutical Industries
- Thermo Fisher Scientific
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca PLC
- Bayer AG
- bioMerieux SA
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Company
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- Hologic Inc.
- Merck & Co. Inc.
- Novo Nordisk A/S
- Organon & Co.
- Pfizer Inc.
- QuidelOrtho Corporation
- Sanofi
- Siemens Healthineers AG
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.

